AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.
|Articles|July 31, 2007
Survey: What Will You Do About Rosiglitazone (Avandia)?
Take this MedPage Today survey.
Advertisement
On Monday, a special FDA advisory panel recommended that rosiglitazone (Avandia) stay on the market, despite an acknowledged increase in ischemic heart risks for type 2 diabetes patients. A meta-analysis published this spring linked the drug to a 43% increase in risk of myocardial infarction.
Advertisement
Related to this article
The ACS 2026 prostate cancer screening guidelines recommend risk-based PSA testing beginning at age 45 or 50, with updated follow-up thresholds.
Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.
Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
2
American Cancer Society Updates Prostate Cancer Screening Guidelines
3
Yoga-Based Cardiac Rehab Improves Quality of Life in Heart Failure Trial
4
Contraindicated Hormone Therapy Prescribing Climbs in Primary Care
5